healthandpharma2d
FDA Approves Innovative ADC Datroway for Unresectable or Metastatic HR+, HER2- Breast Cancer
The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, ...
healthandpharma2d
FDA Approves Sotorasib and Panitumumab Combination: Doubling Survival for KRAS G12C-Mutated Colorectal Cancer
The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...
healthandpharma4d
Regulatory Approval Boosts Pelareorep’s Innovative Oncolytic Virus Therapy for Pancreatic Cancer
Oncolytics Biotech received approval from Germany\u2019s Paul-Ehrlich-Institute to advance Cohort 5 of the GOBLET study, ...
healthandpharma5d
FDA Grants Priority Review to Datopotamab Deruxtecan for Advanced EGFR-Mutated Lung Cancer
Datopotamab deruxtecan (Dato-DXd) has been granted Priority Review from the US FDA for advanced EGFR-mutated non-small cell lung cancer (NSCLC) following prior therapies.
healthandpharma5d
FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small Cell Lung Cancer Patients
Ariceum Therapeutics announced that the FDA has cleared its investigational new drug application to commence a Phase I/II ...
healthandpharma5d
The Internet of Medical Things needs a new security model to fulfil its potential
The Internet of Medical Things (IoMT) is set to radically change the quality of care and outcomes for millions of patients, ...